×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)

UroGen Pharma Stock Forecast, Price & News

$8.11
-0.07 (-0.86%)
(As of 07/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$8.11
$8.52
50-Day Range
$5.12
$8.35
52-Week Range
$4.85
$19.66
Volume
3,468 shs
Average Volume
249,856 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

UroGen Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
134.3% Upside
$19.00 Price Target
Short Interest
Bearish
11.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1,681 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.83) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.33 out of 5 stars

Medical Sector

183rd out of 1,428 stocks

Pharmaceutical Preparations Industry

79th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

UroGen Pharma logo

About UroGen Pharma (NASDAQ:URGN) Stock

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock News Headlines

UroGen Pharma Posts Smaller Q1 Loss
UroGen Pharma earnings preview: what Wall Street is expecting
Earnings Outlook For UroGen Pharma
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
195
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/05/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+134.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-110,820,000.00
Net Margins
-209.30%
Pretax Margin
-206.02%

Debt

Sales & Book Value

Annual Sales
$48.04 million
Book Value
$4.61 per share

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
0.98














UroGen Pharma Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma
or view top-rated stocks.

What is UroGen Pharma's stock price forecast for 2022?

3 equities research analysts have issued 1-year price targets for UroGen Pharma's shares. Their URGN stock forecasts range from $11.00 to $26.00. On average, they anticipate UroGen Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 134.3% from the stock's current price.
View analysts' price targets for UroGen Pharma
or view top-rated stocks among Wall Street analysts.

How has UroGen Pharma's stock price performed in 2022?

UroGen Pharma's stock was trading at $9.51 on January 1st, 2022. Since then, URGN shares have decreased by 14.7% and is now trading at $8.11.
View the best growth stocks for 2022 here
.

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for UroGen Pharma
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings results on Tuesday, May, 10th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.11. The company had revenue of $13.56 million for the quarter, compared to analysts' expectations of $15.62 million. UroGen Pharma had a negative net margin of 209.30% and a negative trailing twelve-month return on equity of 572.49%.
View UroGen Pharma's earnings history
.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 60, Pay $1.25M) (LinkedIn Profile)
  • Mr. Jason Drew Smith, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $616.34k) (LinkedIn Profile)
  • Dr. Mark P. Schoenberg M.D., Chief Medical Officer (Age 64, Pay $579.5k)
  • Mr. Dong Kim, Chief Financial Officer (Age 45)
  • Vincent I. Perrone, Sr. Director of Investor Relations
  • Eric Van Zanten, Sr. Director of Communications
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
  • Dr. Marina Konorty, Exec. VP of R&D and Technical Operations
  • Mr. Jeffrey Bova M.B.A., Chief Commercial Officer
  • Mr. James Ottinger R.ph., Exec. VP of Regulatory Affairs & Quality

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $8.11.

How many employees does UroGen Pharma have?

UroGen Pharma employs 195 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for UroGen Pharma is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.

This page (NASDAQ:URGN) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.